Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study
Journal of the American Academy of Dermatology · 2026
DOI: 10.1016/j.jaad.2025.07.013 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2026. Verfasst von Andrew Blauvelt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Blauvelt Consulting, Annapolis, Maryland. Electronic address: blauveltconsults@gmail.com. Hauptthemen laut MEDLINE: Psoriasis, TYK2 Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: ESK-001, a novel allosteric, highly selective oral tyrosine kinase 2 inhibitor in development for treatment of immune-mediated disorders, was well-tolerated and achieved high levels of target inhibition in phase 1 studies with healthy volunteers. OBJECTIVE: To assess clinical efficacy, safety, and pharmacokinetics of ESK-001 compared to placebo in patients with moderate-to-severe plaque psoriasis. METHODS: STRIDE (NCT05600036, EudraCT Number 2022-002633-34) was a phase 2, double-blinded, 16-week study with patients randomized to 6 treatment groups for 12 weeks of placebo or ESK-001, ranging from 10 mg QD to 40 mg BID. RESULTS: ESK-001 demonstrated a dose-dependent improvement across all end points, with maximal efficacy observed in the highest dose arm (40 mg BID). At week 12, more patients achieved Psoriasis Area and Severity Index-75 in each ESK-001 dose arm compared to placebo: 64% in the 40 mg BID arm vs 0% with placebo (P < .0001). ESK-001 was well-tolerated, with no dose-limiting safety findings and a 2.6% rate of ESK-001 discontinuation due to adverse events. LIMITATIONS: Small sample size per treatment group and 16-week study duration. CONCLUSION: ESK-001 demonstrated significant dose-dependent improvement in signs and symptoms of psoriasis while achieving continuous target inhibition at the highest dose in patients with psoriasis and was well-tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blauvelt Consulting, Annapolis, Maryland. Electronic address: blauveltconsults@gmail.com.
- Department of Dermatology, Charles University, Prague, Czech Republic.
- Division of Dermatology, University of Toronto, Toronto, Ontario, Canada; Probity Medical Research, Waterloo, Ontario, Canada.
- SBA Dermatology, Houston, Texas.
- Alumis Inc, South San Francisco, California.
- Probity Medical Research, Waterloo, Ontario, Canada.
Zitieren
APA
Blauvelt, A., Arenberger, P., Sauder, M. B., Couvillion, M., Rubio, R. G., Vlahakis, N. E., Ucpinar, S., Ma, G., Hitraya, E., Tilley, M. K., Papp, K. A., & STRIDE Investigators (2026). Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.07.013
Vancouver
Blauvelt A, Arenberger P, Sauder MB, Couvillion M, Rubio RG, Vlahakis NE, et al. Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2025.07.013
BibTeX
@article{Blauvelt2026,
author = {Blauvelt, Andrew and Arenberger, Petr and Sauder, Maxwell B and Couvillion, Megan and Rubio, Roman G and Vlahakis, Nicholas E and Ucpinar, Sibel and Ma, Grace and Hitraya, Elena and Tilley, Mera K and Papp, Kim A and STRIDE Investigators, STRIDE Investigators},
title = {Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2025.07.013}
}
EUVIMED